GlassScriptPhysician profile
Vivian Ebrahim
NPI 1073870440
$4,264.66
in general payments reported to CMS, 2019-2025
24 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,169 · 2020: $210 · 2021: $386 · 2022: $464 · 2023: $418 · 2024: $514 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,482.88 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Boston Scientific Corporation | $546.91 | 2019-2023 | Watchman Access System |
| Takeda Pharmaceuticals U.S.A., INC. | $474.64 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $344.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $288.53 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.67 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Ardelyx, INC. | $223.48 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $134.23 | 2023-2025 | |
| Janssen Biotech, INC. | $83.51 | 2019-2024 | Simponi Aria, Simponi, Stelara |
| Medtronic, INC. | $79.84 | 2021 | |
| Neuraxis, INC. | $76.14 | 2025 | |
| Gilead Sciences, INC. | $38.68 | 2019 | |
| Phathom Pharmaceuticals, INC. | $34.41 | 2025 | Voquezna |
| Shionogi INC | $32.72 | 2019 | |
| Alnylam Pharmaceuticals INC. | $28.37 | 2023 | Oxlumo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Erbe USA INC | $28.00 | 2023 | Erbe Vio3 |
| Regeneron Healthcare Solutions, INC. | $27.28 | 2025 | Dupixent |
| Novo Nordisk INC | $22.08 | 2025 | Wegovy |
| Enterra Medical, INC. | $18.95 | 2022 | |
| Capsovision, INC. | $15.45 | 2025 | Capsocam Plus |
| Intercept Pharmaceuticals, INC. | $14.69 | 2020 | |
| Celgene Corporation | $14.61 | 2021 | |
| Braintree Laboratories, INC. | $14.31 | 2023 | Sutab |
| Allergan, INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivian Ebrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.